Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Singular Genomics Systems, Inc. Market Cap
The Singular Genomics Systems, Inc. (OMIC) share price is expected to decrease by 36.87% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered OMIC. Price targets range from $6.5 at the low end to $12.45 at the high end. The current analyst consensus for OMIC is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
OMIC is a stock in Healthcare which has been forecasted to be worth $9.47 as an average. On the higher end, the forecast price is $12.45 USD by from and on the lower end OMIC is forecasted to be $6.5 by Matthew Sykes from Goldman Sachs.
These are the latest 20 analyst ratings of OMIC.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Matthew Sykes Goldman Sachs | Neutral | $6.5 | Maintains | Jul 9, 2024 |
| Matthew Sykes Goldman Sachs | Neutral | $0.75 | Maintains | May 15, 2024 |
| John Sourbeer UBS | Neutral | $0.5 | Maintains | Mar 20, 2024 |
| Matthew Sykes Goldman Sachs | Neutral | $0.85 | Maintains | Jan 23, 2024 |
| Matthew Sykes Goldman Sachs | Neutral | $0.85 | Maintains | Jan 22, 2024 |
| Matthew Sykes Goldman Sachs | Neutral | $1 | Maintains | Aug 10, 2023 |
| Matthew Sykes Goldman Sachs | Neutral | $3 | Maintains | Nov 8, 2022 |
| John Sourbeer UBS | Neutral | $4.5 | Downgrade | Aug 17, 2022 |
| Matthew Sykes Goldman Sachs | Neutral | $3.5 | Downgrade | Aug 10, 2022 |
| Michael Ryskin B of A Securities | Underperform | $3 | Downgrade | Aug 10, 2022 |
| Matthew Sykes Goldman Sachs | Buy | $5 | Maintains | Jul 14, 2022 |
Goldman Sachs | Buy | $9.5 | Maintains | May 11, 2022 |
Goldman Sachs | Buy | $11 | Maintains | Apr 13, 2022 |
B of A Securities | Buy | Upgrade | Jan 7, 2022 | |
Cowen & Co. | Outperform | Initiates | Jun 21, 2021 | |
B of A Securities | Neutral | Initiates | Jun 21, 2021 | |
Goldman Sachs | Buy | Initiates | Jun 21, 2021 | |
JP Morgan | Overweight | Initiates | Jun 21, 2021 |
When did it IPO
2021
Staff Count
255
Country
United States
Sector/Industry
Healthcare/Medical Instruments & Supplies
CEO
Mr. Andrew Spaventa
Market Cap
$37.4M
In 2023, OMIC generated $2.9M in revenue, which was a increase of 280.52% from the previous year. This can be seen as a signal that OMIC's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 19 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Singular Genomics Systems (Nasdaq: OMIC) received a non-binding acquisition proposal from Concentra Biosciences for $12.00 per share in cash, with potential contingent value rights for stockholders.
Why It Matters - Singular Genomics' acquisition proposal at $12 per share signals potential value realization for shareholders, impacting stock price and investor sentiment around the company's future prospects.
Thu, 19 Sep 2024
Sentiment - POSITIVE
Source - Benzinga
Summary - U.S. stocks closed lower on Wednesday, but notable insider trades were reported, indicating potential shifts in investor sentiment or confidence among company executives.
Why It Matters - Notable insider trades can indicate insider confidence or concerns about a company's future, potentially influencing stock performance and investor sentiment.
Thu, 12 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Singular Genomics Systems received a non-binding acquisition proposal from Deerfield Management for $10.00 per share, seeking to acquire all outstanding shares not already owned by them.
Why It Matters - The acquisition proposal at $10.00 per share from Deerfield could indicate a premium valuation for Singular Genomics, impacting stock price and investor sentiment significantly.
Tue, 13 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Singular Genomics Systems, Inc. (NASDAQ: OMIC) will hold its Q2 2024 earnings call on August 13, 2024, at 4:30 PM ET, featuring key executives and analysts from TD Cowen and Goldman Sachs.
Why It Matters - The earnings call provides insights into Singular Genomics' financial performance and strategic direction, influencing investor sentiment and stock valuation.
Tue, 30 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Singular Genomics Systems, Inc. (Nasdaq: OMIC) will report Q2 2024 financial results on August 13, 2024, after market close, with a conference call scheduled for 1:30 PM PT.
Why It Matters - Singular Genomics' upcoming financial report could influence its stock performance, impacting investor sentiment based on revenue growth or profitability in a competitive biotech sector.
Mon, 15 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Singular Genomics (Nasdaq: OMIC) has regained compliance with Nasdaq's minimum bid price requirement, ensuring continued listing on the Nasdaq Capital Market.
Why It Matters - Singular Genomics' compliance with Nasdaq's minimum bid price requirement enhances its credibility and stability, potentially boosting investor confidence and share value.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
